Market growth shows signs of decline in several gene silencing segments surveyed. Prospective users grow.

Carlsbad, Calif. – December 12, 2010 – Today, Percepta Associates announced the launch of the 2010 Gene Silencing Series 3 Life Science DashboardTM market research report which draws comparisons to key market indicator data reported in Percepta’s 2008 Gene Silencing Dashboard. This report provides rapid access to actionable key market indicators for the gene silencing market, such as market size, competitive shares, growth rates, customer satisfaction/ propensity to switch, and end-user practices, in an ‘at a glance’ easy to understand format, for the following gene silencing market segments:

  • RNAi screens using siRNA libraries
  • In vivo induction of siRNA from a plasmid
  • In vivo digestion of long dsRNA using dicer enzymes
  • Expression of siRNA in vitro
  • Use of PCR mediated expression cassettes to generate siRNAs
  • Instrument-mediated delivery of synthetic siRNA into cells
  • Lipid-mediated delivery of synthetic siRNA into cells
  • Instrument-mediated delivery of plasmid encoding siRNA into cells
  • Lipid-mediated delivery of plasmid encoding siRNA into cells
  • Viral delivery of siRNA vectors into cells
  • Use of reporter systems to track gene knockdown

Leading suppliers for these gene silencing segments include Life Technologies (NASDAQ: LIFE), Lonza (XETRA: LO3.DE) and Thermo Fisher Scientific (NYSE: TMO). Findings show four out of the eleven market segments have projected growth rates greater than 10%, and a measurable .increase in the number of prospective researchers performing gene silencing experiments relative to 2008. However, the overall market growth rate, in comparison to the 2008 findings has declined. Additional findings reveal more than 50% of the respondents in 5 of 11 segments expressed interest in switching primary suppliers for performance reasons. However, interest in switching has fallen in comparison to 2008 results.

“The Gene Silencing market continues to grow at an attractive rate for some segments while leading suppliers of some segments may see a pull back in research activity. It is clear from this study that customers are looking for improved performance in how effectively they can shutdown expression of target genes.”, said Anne St. Louis, Director at Percepta Associates. “This dashboard will help companies identify where those product segment opportunities are so they can steer the direction of their businesses accordingly.”

Gene silencing is a method of artificially inducing a shutdown of specific targeted genes expressed in cells. Gene silencing methods are increasingly used in gene function studies, drug target validation, and the development of therapeutics. The Gene Silencing Series 3 Life Science DashboardTM was developed from responses to a 21-question survey completed by 281 scientists predominantly located in North America and Europe.

To view Gene Silencing dashboard sample data and the survey questionnaire visit:
http://www.perceptaassociates.com/publications/10_gene_silencing_overview.shtml

About Percepta
Founded in 2005 in Carlsbad, California Percepta Associates is a specialized consultancy providing expert market research, strategic business planning, portfolio management, product and corporate branding and marketing communications services to life science research suppliers globally. For more information visit: www.perceptaassociates.com

CONTACT:
Percepta Associates Inc.
Anne St. Louis
Director
Phone: 760 431 6300
Email: AStLouis@perceptaassociates.com